Gain of 3q26: A genetic marker in low-grade squamous intraepithelial lesions (LSIL) of the uterine cervix

Seppo, Antti; Jalali, G. Reza; Babkowski, Robert; Symiakaki, Hera; Rodolakis, Alexandros; Tafas, Triantafyllos; Tsipouras, Petros; Kilpatrick, Michael W.

doi:10.1016/j.ygyno.2009.03.031

Cited by 27 publications

(14 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A 3q26 gain has been reported to increase in frequency from normal cervical epithelium, to CIN, and then to invasive carcinoma [24,25]. Recent studies have examined the use of 3q26 gain measurements as a predictor of regression or progression of cervical LSIL [26][27][28]. Prospective studies in larger numbers of women with LSIL are ongoing to establish more reliable sensitivity, specificity, PPV and NPV data.…”

Section: Discussionmentioning

confidence: 99%

Methylated ZNF582 gene as a marker for triage of women with Pap smear reporting low-grade squamous intraepithelial lesions — A Taiwanese Gynecologic Oncology Group (TGOG) study

Lin

Chen

Chang

et al. 2014

Gynecologic Oncology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Methylated ZNF582 gene as a marker for triage of women with Pap smear reporting low-grade squamous intraepithelial lesions — A Taiwanese Gynecologic Oncology Group (TGOG) study

Lin

Chen

Chang

et al. 2014

Gynecologic Oncology

View full text Add to dashboard Cite

“…Similarly, studies that evaluated immunostaining for p16 tumor suppressor protein as a surrogate biomarker for the presence of highrisk HPV in cytology smears that had subsequent CIN 2ϩ or CIN 3ϩ biopsy results have shown that performance characteristics were not sufficient to add value as a triage test (87,(114)(115)(116). Other biomarkers, such Ki-67 to detect deregulated cell cycle proliferation, dual staining for Ki-67 plus p16, and BD ProEx C (Becton, Dickinson and Company, Franklin Lakes, NJ) to detect aberrant S-phase induction, genes with aberrant DNA methylation, and chromosomal aberrations in the telomerase RNA gene have not proven useful, or there is insufficient evidence related to the clinical value of the test (117)(118)(119)(120)(121)(122)(123). Further, the leading medical professional societies have not recommended these tests in their cervical cancer screening guidelines.…”

Section: Commercially Available Test Systems For Hpv Detection In Thementioning

confidence: 99%

Human Papillomavirus Laboratory Testing: the Changing Paradigm

2016

View full text Add to dashboard Cite

SUMMARYHigh-risk human papillomaviruses (HPVs) cause essentially all cervical cancers, most anal and oropharyngeal cancers, and some vaginal, vulvar, and penile cancers. Improved understanding of the pathogenesis of infection and the availability of newer tests are changing the approach to screening and diagnosis. Molecular tests to detect DNA from the most common high-risk HPVs are FDA approved for use in conjunction with cytology in cervical cancer screening programs. More-specific tests that detect RNA from high-risk HPV types are now also available. The use of molecular tests as the primary screening tests is being adopted in some areas. Genotyping to identify HPV16 and -18 has a recommended role in triaging patients for colposcopy who are high-risk HPV positive but have normal cytology. There are currently no recommended screening methods for anal, vulvar, vaginal, penile, or oropharyngeal HPV infections. HPV testing has limited utility in patients at high risk for anal cancer, but p16 immunohistochemistry is recommended to clarify lesions in tissue biopsy specimens that show moderate dysplasia or precancer mimics. HPV testing is recommended for oropharyngeal squamous cell tumors as a prognostic indicator. Ongoing research will help to improve the content of future guidelines for screening and diagnostic testing.

show abstract

“…We therefore plan to extend the application of miniaturized FISH to the detection of other genetic diseases such as bladder or cervical cancer (21,22), where screening strategies can be envisioned. …”

Section: Resultsmentioning

confidence: 99%

Miniaturized FISH for Screening of Onco-Hematological Malignancies

Zanardi

Bandiera

Corsini³

et al. 2010

BioTechniques

View full text Add to dashboard Cite

Fluorescence in situ hybridization (FISH) represents a major step in the analysis of chromosomal aberrations in cancer. It allows the precise detection of specific rearrangements, both for diagnostic and prognostic purposes. Here we present a miniaturized FISH method performed on fresh and fixed hematological samples. This procedure has been developed together with a microfluidic device that integrates cluster-assembled nanostructured TiO2 (ns-TiO2) as a nanomaterial promoting hematopoietic cell immobilization in conditions of shear stress. As a result of miniaturization, FISH can be performed with at least a 10-fold reduction in probe usage and minimal cell requirements, creating the possibility of using FISH in genetic screening applications. We developed the protocol on tumor cells and bone marrow (BM) from a normal donor using commercially sex-specific and onco-hematology probes. The procedure was then validated using either BM or peripheral blood (PB) from six patients with hematological diseases, each associated with different genetic lesions. Miniaturized FISH demonstrated comparable performance to standard FISH, indicating that it is suitable for genetic screenings, in research, and in clinical settings for the diagnosis of samples from onco-hematological malignancies.

show abstract

Gain of 3q26: A genetic marker in low-grade squamous intraepithelial lesions (LSIL) of the uterine cervix

Cited by 27 publications

References 23 publications

Methylated ZNF582 gene as a marker for triage of women with Pap smear reporting low-grade squamous intraepithelial lesions — A Taiwanese Gynecologic Oncology Group (TGOG) study

Methylated ZNF582 gene as a marker for triage of women with Pap smear reporting low-grade squamous intraepithelial lesions — A Taiwanese Gynecologic Oncology Group (TGOG) study

Human Papillomavirus Laboratory Testing: the Changing Paradigm

Miniaturized FISH for Screening of Onco-Hematological Malignancies

Contact Info

Product

Resources

About